Clinical pharmacokinetics of etoposide during 120 hours continuous infusions in solid tumours
- 1 November 1990
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 62 (5) , 840-841
- https://doi.org/10.1038/bjc.1990.390
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Superiority of perfusion over bolus administration in cancer chemotherapy: Proposition of a compartmental modelMedical Hypotheses, 1989
- A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study.Journal of Clinical Oncology, 1989
- Adaptive control of etoposide administration: Impact of interpatient pharmacodynamic variabilityClinical Pharmacology & Therapeutics, 1989
- Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial.Journal of Clinical Oncology, 1987
- The Clinical Pharmacology of Etoposide and TeniposideClinical Pharmacokinetics, 1987
- Etoposide: A pharmacokinetic profile including an assessment of bioavailabilityMedical Oncology and Tumor Pharmacotherapy, 1986
- PHARMACOKINETICS OF ETOPOSIDE IN PATIENTS WITH ABNORMAL RENAL AND HEPATIC-FUNCTION1986
- Anticancer drug pharmacodynamicsCancer Chemotherapy and Pharmacology, 1985
- Reporting results of cancer treatmentCancer, 1981